In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates

MLA

Nam Yong Lee, et al. In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates. Apr. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2e5ebaa898ab9485c8f563dd948448c5&authtype=sso&custid=ns315887.

APA

Nam Yong Lee, Byung Woo Jhun, Won-Jung Koh, Hee Jae Huh, Su Young Kim, & Dae Hun Kim. (2021). In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates.

Chicago

Nam Yong Lee, Byung Woo Jhun, Won-Jung Koh, Hee Jae Huh, Su Young Kim, and Dae Hun Kim. 2021. “In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates,” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2e5ebaa898ab9485c8f563dd948448c5&authtype=sso&custid=ns315887.